Poet Technologies Stock Crashes as Marvell Sale Falls Through

What happened

Last week, Poet Technologies touted a major sale to Marvell, but the deal has now unraveled, sending shares sharply lower. The Motley Fool reported on April 27 that Poet 'spoke too soon' about the sale, suggesting the company overstated its commercial progress. This event is a significant credibility blow, as the reported sale was seen as a key validation of Poet's optical engine technology and a step toward revenue inflection. The DeepValue report had already assigned a 'WAIT' rating, warning that the stock priced in commercialization before shipment evidence. This development increases the risk that the company's manufacturing readiness milestones in Q2/Q3 2026 may not translate into reliable customer orders.

Implication

The failed Marvell sale casts a long shadow over Poet's commercial narrative. Investors should wait for verifiable production orders and evidence of manufacturing execution at NationGate/Globetronics before considering entry. The PFIC confusion and now this misstep suggest management's communication is unreliable, raising the risk premium. The stock may trade closer to the bear case of $9 if revenue milestones slip. The 3-6 month reassessment window is critical; any further disappointment could lead to a thesis break.

Thesis delta

This news weakens the thesis that Poet is on the cusp of a revenue inflection. The reported sale to Marvell was a key catalyst for the recent stock surge, and its collapse suggests the company's commercial progress is less advanced than portrayed. Investors must now demand independent verification of orders and production ramp before assigning any value to future sales.